Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Edaravone: A new therapeutic approach for the treatment of acute stroke
Authors: Kiyoshi Kikuchi
Ko Ichi Kawahara
Naohisa Miyagi
Hisaaki Uchikado
Terukazu Kuramoto
Yoko Morimoto
Salunya Tancharoen
Naoki Miura
Kazunori Takenouchi
Yoko Oyama
Binita Shrestha
Fumiyo Matsuda
Yoshihiro Yoshida
Shinichiro Arimura
Kentaro Mera
Ko Ichi Tada
Narimasa Yoshinaga
Ryuichi Maenosono
Yoshiko Ohno
Teruto Hashiguchi
Ikuro Maruyama
Minoru Shigemori
Yame General Hospital
Kagoshima University Faculty of Medicine
Kurume University School of Medicine
Omuta City General Hospital
Mahidol University
Kagoshima University
Keywords: Medicine
Issue Date: 1-Dec-2010
Citation: Medical Hypotheses. Vol.75, No.6 (2010), 583-585
Abstract: Acute stroke, including acute ischemic stroke (AIS) and acute hemorrhagic stroke, (AHS) is a common medical problem with particular relevance to the demographic changes in industrialized societies. In recent years, treatments for AIS have emerged, including thrombolysis with tissue plasminogen activator (t-PA). Although t-PA is the most effective currently available therapy, it is limited by a narrow therapeutic time window and side effects, and only 3% of all AIS patients receive thrombolysis. Edaravone was originally developed as a potent free radical scavenger and, since 2001, has been widely used to treat AIS in Japan. It was shown that edaravone extended the narrow therapeutic time window of t-PA in rats. The therapeutic time window is very important for the treatment of AIS, and early edaravone treatment is more effective. Thus, more AIS patients might be rescued by administering edaravone with t-PA. Meanwhile, edaravone attenuates AHS-induced brain edema, neurologic deficits and oxidative injury in rats. Although edaravone treatment is currently only indicated for AIS, it does offer neuroprotective effects against AHS in rats. Therefore, we hypothesize that early administration of edaravone can rescue AHS patients as well as AIS patients. Taken together, our findings suggest that edaravone should be immediately administered on suspicion of acute stroke, including AIS and AHS. © 2010 Elsevier Ltd.
ISSN: 03069877
Appears in Collections:Scopus 2006-2010

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.